Wilson Marc 4
4 · Crinetics Pharmaceuticals, Inc. · Filed Sep 30, 2024
Insider Transaction Report
Form 4
Wilson Marc
CFO
Transactions
- Sale
Common Stock
2024-09-26$51.11/sh−25,000$1,277,750→ 111,092 total - Exercise/Conversion
Common Stock
2024-09-26$15.29/sh+25,000$382,250→ 136,092 total - Exercise/Conversion
Stock option (Right to Buy)
2024-09-26−25,000→ 89,000 totalExercise: $15.29Exp: 2031-02-26→ Common Stock (25,000 underlying)
Footnotes (3)
- [F1]The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $51.11 per share. The range of sales prices on the transaction date was $50.28 to $51.54 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- [F3]1/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.